The Insider and Sr. VP & Chief Medical Officer of Enanta Pharmaceuticals, Inc. (ENTA), Nathalie Adda, Unloaded 4,155 Shares; Ellsworth Growth and Income Fund LTD. (NYSEAMERICAN:ECF) Shorts Decreased By 32.21%

June 20, 2018 - By Marguerite Chambers

Ellsworth Growth and Income Fund LTD. (NYSEAMERICAN:ECF) had a decrease of 32.21% in short interest. ECF’s SI was 26,100 shares in June as released by FINRA. Its down 32.21% from 38,500 shares previously. With 27,700 avg volume, 1 days are for Ellsworth Growth and Income Fund LTD. (NYSEAMERICAN:ECF)’s short sellers to cover ECF’s short positions. The stock increased 0.32% or $0.03 during the last trading session, reaching $9.55. About 16,192 shares traded. Ellsworth Growth and Income Fund Ltd. (NYSEAMERICAN:ECF) has risen 5.53% since June 20, 2017 and is uptrending. It has underperformed by 7.04% the S&P500.

Among 8 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 3 have Buy rating, 1 Sell and 4 Hold. Therefore 38% are positive. Enanta Pharmaceuticals Inc has $135 highest and $16 lowest target. $72.29’s average target is -36.69% below currents $114.18 stock price. Enanta Pharmaceuticals Inc had 27 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Friday, September 15 by Robert W. Baird. The firm has “Hold” rating by Robert W. Baird given on Thursday, February 8. The company was maintained on Wednesday, April 4 by RBC Capital Markets. JP Morgan maintained Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) on Tuesday, August 9 with “Overweight” rating. The stock of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has “Buy” rating given on Saturday, August 8 by TheStreet. JMP Securities upgraded it to “Mkt Outperform” rating and $32 target in Friday, October 23 report. The rating was downgraded by JP Morgan on Thursday, February 8 to “Neutral”. The stock has “Market Outperform” rating by JMP Securities on Tuesday, July 11. On Thursday, February 8 the stock rating was downgraded by J.P. Morgan to “Hold”. Robert W. Baird maintained it with “Neutral” rating and $36 target in Tuesday, August 8 report.

Analysts await Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report earnings on August, 6. They expect $0.94 earnings per share, up 313.64% or $1.38 from last year’s $-0.44 per share. ENTA’s profit will be $18.11 million for 30.37 P/E if the $0.94 EPS becomes a reality. After $0.61 actual earnings per share reported by Enanta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 54.10% EPS growth.

The stock increased 0.14% or $0.16 during the last trading session, reaching $114.18. About 170,187 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 217.72% since June 20, 2017 and is uptrending. It has outperformed by 205.15% the S&P500. Some Historical ENTA News: ; 08/05/2018 – ENANTA PHARMACEUTICALS INC – ROYALTY REVENUE FOR QUARTER INCREASED TO $44.0 MLN DUE TO INCREASE IN ABBVIE’S MAVYRET SALES; 12/04/2018 – Enanta to Present New Data for Core Inhibitor for Hepatitis B Virus and FXR Agonist EDP-305 for NASH at The International Liver Congress™ 2018; 08/05/2018 – ENANTA 2Q EPS 61C, EST. 53C; 14/05/2018 – Stonepine Capital Management LLC Exits Position in Enanta; 22/04/2018 – DJ Enanta Pharmaceuticals Inc, Inst Holders, 1Q 2018 (ENTA); 08/05/2018 – Enanta Pharmaceuticals 2Q EPS 61c; 14/05/2018 – Janus Henderson Group Buys New 2.6% Position in Enanta; 09/05/2018 – ENANTA PHARMACEUTICALS INC ENTA.O : RBC RAISES TARGET PRICE TO $100.00 FROM $80; 08/05/2018 – ENANTA 2Q REV. $44.0M, EST. $40.8M; 08/05/2018 – Enanta Pharmaceuticals 2Q Rev $44M

Investors sentiment increased to 1.66 in Q1 2018. Its up 0.08, from 1.58 in 2017Q4. It improved, as 11 investors sold Enanta Pharmaceuticals, Inc. shares while 45 reduced holdings. 42 funds opened positions while 51 raised stakes. 14.18 million shares or 4.00% more from 13.64 million shares in 2017Q4 were reported. Franklin Res has 285,800 shares for 0.01% of their portfolio. Susquehanna Int Grp Llp stated it has 8,036 shares. Arizona State Retirement reported 22,697 shares. Renaissance Tech Ltd Company has invested 0.07% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). National Bank Of Ny Mellon accumulated 0.01% or 249,376 shares. Two Sigma Secs Lc holds 0% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 3,022 shares. Bluemountain Mngmt Llc owns 7,398 shares. New York-based Indexiq Ltd Llc has invested 0.06% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). State Of Alaska Department Of Revenue has 4,640 shares. Metropolitan Life Insurance Ny reported 0% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Perceptive Advsrs Lc reported 0.02% stake. 593,310 were reported by Dimensional Fund Advsrs Limited Partnership. The Ontario – Canada-based Td Asset Mgmt Incorporated has invested 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Alliancebernstein Limited Partnership owns 35,230 shares. Northern Corporation reported 0% stake.

Sale amounting to roughly $477,222 U.S. Dollars was disclosed in a public document submitted to the (SEC) on June 19, 2018. According to which, Nathalie Adda, the Sr. VP & Chief Medical Officer of Enanta Pharmaceuticals Inc also an insider of the company had sold a total of 4,155 shares – ( at $114.9 for a share ). she right now possess 0.02% of the market capitalization of the company.

Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company has market cap of $2.20 billion. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. It has a 43.73 P/E ratio. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

More notable recent Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on June 06, 2018, also Seekingalpha.com with their article: “Intercept And Obeticholic Acid Therapy: Discerning Scientific Facts From Fallacies On Cholestatic Liver Diseases” published on June 12, 2018, Investorplace.com published: “2 Stable and 2 Speculative Biotech Stocks to Buy” on June 15, 2018. More interesting news about Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) were released by: Globenewswire.com and their article: “Factors of Influence in 2018, Key Indicators and Opportunity within Assembly Biosciences, MGP Ingredients, Globant ..” published on May 29, 2018 as well as Seekingalpha.com‘s news article titled: “Lipotoxicity And Liver Diseases-NASH And PBC: Is Enanta A Player Or Spectator?” with publication date: June 01, 2018.

Since March 19, 2018, it had 0 insider buys, and 5 insider sales for $6.03 million activity. 25,000 shares were sold by Luly Jay R., worth $2.65M on Wednesday, May 16. Adda Nathalie had sold 4,225 shares worth $361,560 on Monday, April 16. On Monday, March 19 MELLETT PAUL J sold $778,331 worth of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) or 9,000 shares.

Since January 17, 2018, it had 2 buys, and 0 insider sales for $10,750 activity. Bizzell Kinchen C also bought $4,996 worth of Ellsworth Growth and Income Fund Ltd. (NYSEAMERICAN:ECF) shares. Dinsmore James Andrew had bought 600 shares worth $5,754 on Wednesday, January 17.

Investors sentiment increased to 1 in Q1 2018. Its up 0.09, from 0.91 in 2017Q4. It is positive, as 2 investors sold Ellsworth Growth and Income Fund Ltd. shares while 8 reduced holdings. 5 funds opened positions while 5 raised stakes. 3.34 million shares or 0.91% less from 3.38 million shares in 2017Q4 were reported. North Star Inv Mngmt reported 0% of its portfolio in Ellsworth Growth and Income Fund Ltd. (NYSEAMERICAN:ECF). Saba Cap Mngmt L P invested in 0.04% or 79,071 shares. Hightower Limited Company owns 60,591 shares for 0% of their portfolio. Meridian Counsel Inc, a California-based fund reported 25,157 shares. 3,727 are held by Blue Bell Private Wealth Mngmt Limited Liability Corporation. Illinois-based Wolverine Asset Management Llc has invested 0.01% in Ellsworth Growth and Income Fund Ltd. (NYSEAMERICAN:ECF). Pnc Financial Services Group Inc stated it has 0% in Ellsworth Growth and Income Fund Ltd. (NYSEAMERICAN:ECF). Aviance Cap Prtn Limited Liability Corp owns 88,546 shares. Altfest L J And invested in 91,336 shares. Guggenheim Limited Liability has invested 0.01% in Ellsworth Growth and Income Fund Ltd. (NYSEAMERICAN:ECF). Royal State Bank Of Canada accumulated 17,960 shares. Wells Fargo And Mn reported 420,170 shares or 0% of all its holdings. Rmb Capital Mgmt Ltd Limited Liability Company holds 34,491 shares or 0.01% of its portfolio. 249 are owned by Bancorp Of America De. Morgan Stanley reported 1.04M shares stake.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>